NEW YORK, Sept. 13, 2017 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Northern District of Ohio on behalf of investors who purchased TransDigm Group Incorporated ("TransDigm") (NYSE:TDG) securities between May 10, 2016 and January 19, 2017.
Click here to learn about the case: http://www.wongesq.com/pslra-sb/transdigm-group-incorporated?wire=3. There is no cost or obligation to you.
According to the complaint, throughout the Class Period, the Company issued materially false and misleading statements and/or failed to disclose that: (1) TransDigm’s growth and profitability were artificially inflated as a result of its illicit business practices; (2) the Company used exclusive distributors to make noncompetitive government bids seem competitive; (3) TransDigm subsidiaries failed to list TransDigm as a parent entity when submitting government bids; and (4) as a result of the foregoing, Defendants’ statements about TransDigm’s business, operations, and prospects were false and misleading and/or lacked a reasonable basis.
If you suffered a loss in TransDigm you have until October 10, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra-sb/transdigm-group-incorporated?wire=3.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]


AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
FDA Approves Mitapivat for Anemia in Thalassemia Patients
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage
Italy Fines Apple €98.6 Million Over App Store Dominance
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 



